ImmunoGen Inc (NASDAQ:IMGN)

14.01
Delayed Data
As of Jul 02
 -0.26 / -1.82%
Today’s Change
5.34
Today|||52-Week Range
15.88
+129.67%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. It also have developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream and then release it once the therapy has reached and entered a cancer cell. The company also uses antibody-drug conjugate targeted antibody payload technology together with strong antibody expertise to develop its own product candidates. ImmunoGen was founded in March 1981 and is headquartered in Waltham, MA.

Contact Information

ImmunoGen, Inc.
830 Winter Street
Waltham Massachusetts 02451-1477
P:(781) 895-0600
Investor Relations:

Employees

Shareholders

Mutual fund holders50.54%
Other institutional36.89%
Individual stakeholders1.14%

Top Executives

Daniel M. JuniusPresident, Chief Executive Officer & Director
David B. JohnstonChief Financial Officer & Executive Vice President
Sandra E. PooleSenior Vice President-Technical Operations
Richard J. GregoryChief Scientific Officer & Executive VP-Research
Anna BerkenblitChief Medical Officer & Vice President

To view my watchlist

Not a member yet?

Sign up now for a free account